Omep 40 mg/vial (IV Injection)
40 mg vial: ৳ 80.00
Medicine Details
Category | Details |
---|---|
Generic | Omeprazole |
Company | Aristopharma ltd |
Also available as |
Indications
- Gastric and duodenal ulcer
- NSAID-associated duodenal and gastric ulcer
- Prophylaxis in patients with a history of NSAID-associated duodenal and gastric ulcer
- Gastro-esophageal reflux disease
- Long-term management of acid reflux disease
- Acid-related dyspepsia
- Severe ulcerating reflux esophagitis
- Prophylaxis of acid aspiration during general anesthesia
- Zollinger-Ellison syndrome
- Helicobacter pylori-induced peptic ulcer
Pharmacology
- Inhibitor of gastric acid secretion
- Blocks hydrogen-potassium-adenosine triphosphatase (H+/K+ ATPase) enzyme system
- Onset of antisecretory effect within one hour
- Maximum effect occurring within two hours
- Inhibition of secretion lasts up to 72 hours
- Return of secretory activity gradually over 3 to 5 days after discontinuation
Dosage
- 20 mg once daily for benign gastric and duodenal ulcer
- 40 mg daily for severe or recurrent cases
- 10-20 mg daily for duodenal ulcer prevention
- 20 mg once daily for NSAID-associated duodenal or gastric ulcer for 4 weeks
- 20 mg once daily for 4 weeks for GERD
- 40 mg once daily for refractory GERD for 8 weeks
- 10-20 mg daily for long-term management of acid reflux disease
- 10-20 mg once daily for acid-related dyspepsia
- 40 mg prophylaxis of acid aspiration before surgery
- 60 mg once daily for Zollinger-Ellison syndrome
- 20 mg twice daily with antimicrobial agents for H.pylori eradication regimen
- 10-40 mg once daily for severe ulcerating reflux esophagitis
- 40 mg slowly as IV injection for prophylaxis of acid aspiration
- 40 mg Omeprazole IV once daily for duodenal ulcer, gastric ulcer or reflux esophagitis where oral medication is inappropriate
- Initial 60 mg daily dose for Zollinger-Ellison syndrome given intravenously
- Omeprazole IV infusion over 20-30 minutes or more
- Pediatric use: 10-40 mg once daily based on body-weight
Administration
- IV Injection for intravenous administration only
- IV infusion over 20-30 minutes or more
- Reconstitution required with specific volumes of saline or dextrose for infusion
- Solution for IV injection should be used within 4 hours of reconstitution
- Solution for IV infusion should be used within 12 hours when dissolved in saline and within 6 hours when dissolved in 5% Dextrose
Interaction
- Reduction in absorption of ketoconazole during treatment
- Metabolism via cytochrome P450 leading to delay in elimination of diazepam, phenytoin, and warfarin
- Plasma concentration increase during concomitant administration with clarithromycin
- No evidence of interaction with various drugs such as phenacetin, theophylline, caffeine, propranolol, etc.
- Increased bioavailability of digoxin due to increased intragastric pH during simultaneous treatment with Omeprazole
- No effect on absorption by alcohol or food
- Useful interactions during H.pylori eradication and continuation of certain treatments
Contraindications
- Known hypersensitivity to Omeprazole
- Need to exclude possibility of malignancy before treatment if gastric ulcer is suspected
Side Effects
- Mild and reversible adverse reactions
- Skin rash, urticaria, and pruritus
- Photosensitivity, bullous eruption, erythema multiforme, angioedema, and alopecia reported in isolated cases
- Diarrhea, headache, constipation, nausea/vomiting, and abdominal pain
- Dry mouth, stomatitis, and candidiasis reported in isolated cases
- Paraesthesia, dizziness, and light-headedness
- Mental confusion, agitation, depression, and hallucinations predominantly in severely ill patients
- Arthritic and myalgic symptoms, blurred vision, taste disturbance, gynaecomastia, and changes in liver enzymes observed in isolated cases
Pregnancy & Lactation
- No adverse effects reported on pregnancy or the health of the fetus/newborn child
- Use during pregnancy indicated
- No information available on passage into breast milk or effects on the neonate
- Breastfeeding discontinuation recommended if essential use of Omeprazole
- Safety and effectiveness not established in pediatric patients less than 18 years of age
Precautions & Warnings
- Avoid concomitant use of clopidogrel and Omeprazole
- Increased risk for osteoporosis-related fractures with PPI therapy
- Atrophic gastritis noted in patients treated long-term
- Concomitant use with methotrexate may lead to toxicities
Therapeutic Class
- Proton Pump Inhibitor
Storage Conditions
- Keep in a dry place away from light and heat
- Keep out of the reach of children
Related Brands
- Omepra 20 mg (Capsule (Enteric Coated)) - alco-pharma-ltd
- Omepra 40 mg (Capsule (Enteric Coated)) - alco-pharma-ltd
- Omeprol 20 mg (Capsule (Enteric Coated)) - ziska-pharmaceuticals-ltd
- Omeprol 40 mg (Capsule (Enteric Coated)) - ziska-pharmaceuticals-ltd
- Omeprol 40 mg/vial (IV Injection) - ziska-pharmaceuticals-ltd